US-based diabetes technology company Tandem Diabetes Care has partnered with the University of Virginia (UVA) Centre for Diabetes Technology to enhance insulin delivery.
The collaboration is designed to advance the research and development of fully automated closed-loop insulin delivery systems.
The multi-year research partnership will leverage Tandem’s expertise in insulin delivery devices, algorithm implementation, and data management.
It will also use the UVA Centre for Diabetes Technology’s work to improve care for patients with diabetes.
It will leverage UVA’s technology-driven interventions, and ability to translate automated insulin delivery (AID) algorithms into medical devices used worldwide.
UVA Centre for Diabetes Technology associate director for research Marc Breton said: “After more than 10 years working with the Tandem team, this is an exciting new beginning for our collaboration to serve patients with diabetes.
“Together, we will expand our research efforts into automated insulin delivery with the goal of once more substantially enhancing care and quality of life for patients around the world.”
Under the collaboration, Tandem will provide the UVA Centre for Diabetes Technology with funding, technology, and supplies to support the research and potential clinical studies.
It will involve scientists, clinicians, and functional experts of both organisations.
Tandem said the collaboration will expand its ongoing research to advance automated closed-loop insulin delivery technology.
Furthermore, the partnership may advance clinical research to support regulatory approval for its next-generation AID systems, said the diabetes technology company.
Tandem Diabetes Care president and CEO John Sheridan said: “Our past work with UVA, including research related to our automated insulin delivery systems as part of the International Diabetes Closed Loop trials, helped contribute to life-changing products for the diabetes community.
“We believe this research collaboration will continue on our joint history of delivering new innovations that can further improve the lives of people living with diabetes.”
